ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2015, Pages 1367-1380

  Duraffour, Sophie ^a   Lorenzo, María M ^b   Zöller, Gudrun ^c   Topalis, Dimitri ^a   Grosenbach, Doug ^d   Hruby, Dennis E ^d   Andrei, Graciela ^a   Blasco, Rafael ^b   Meyer, Hermann ^c   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INIA   (Spain)

^c BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

^d SIGA Technologies Incorporated   (United States)

Author keywords

Antivirals; Drug resistance; Mechanisms of action; Poxvirus; Vaccinia virus

Indexed keywords

CIDOFOVIR; F13L PHOSPHOLIPASE; PHOSPHOLIPASE; TECOVIRIMAT; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; ISOINDOLE DERIVATIVE; PROTEIN BINDING; ST-246;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CAMELPOX VIRUS; CELL CULTURE; CELL PROLIFERATION; COWPOX VIRUS; EC50; GENE MUTATION; GENE SEQUENCE; GOLGI COMPLEX; HUMAN; HUMAN CELL; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; PHENOTYPE; POXVIRUS INFECTION; VACCINIA VIRUS; VIROGENESIS; VIRUS GENE; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PHYSIOLOGY; PROTEIN CONFORMATION; VIRAL PLAQUE ASSAY; VIRUS ASSEMBLY; VIRUS CULTURE;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; COWPOX VIRUS; DRUG RESISTANCE, VIRAL; HUMANS; ISOINDOLES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MUTATION; ORTHOPOXVIRUS; PHOSPHOLIPASES; PROTEIN BINDING; PROTEIN CONFORMATION; SERIAL PASSAGE; VACCINIA VIRUS; VIRAL PLAQUE ASSAY; VIRUS ASSEMBLY; VIRUS CULTIVATION;

EID: 84929736042     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku545     Document Type: Article

References (67)

1. Shchelkunov SN. An increasing danger of zoonotic orthopoxvirus infections. PLoS Pathog 2013; 9: e1003756.
2. Favier AL, Flusin O, Lepreux S et al. Necrotic ulcerated lesion in a young boy caused by cowpox virus infection. Case Rep Dermatol 2011; 3: 186-94.
3. Haase O, Moser A, Rose C et al. Generalized cowpox infection in a patient with Darier disease. Br J Dermatol 2011; 164: 1116-8.
4. Pelkonen PM, Tarvainen K, Hynninen A et al. Cowpox with severe generalized eruption, Finland. Emerg Infect Dis 2003; 9: 1458-61.
5. Vogel S, Sardy M, Glos K et al. The Munich outbreak of cutaneous cowpox infection: transmission by infected pet rats. Acta Derm Venereol 2012; 92:126-31.
6. Schatzmayr HG, Costa RV, Goncalves MC et al. Human and animal infections by vaccinia-like viruses in the state of Rio de Janeiro: a novel expanding zoonosis. Vaccine 2011; 29 Suppl 4: D65-9.
7. Medaglia ML, Pessoa LC, Sales ER et al. Spread of Cantagalo virus to northern Brazil. Emerg Infect Dis 2009; 15: 1142-3.
8. Bhanuprakash V, Venkatesan G, Balamurugan V et al. Zoonotic infections of buffalopox in India. Zoonoses Public Health 2010; 57: e149-55.
9. McCollum AM, Damon IK. Human monkeypox. Clin Infect Dis 2014; 58: 260-7.
10. Duraffour S, Meyer H, Andrei G et al. Camelpox virus. Antiviral Res 2011; 92: 167-86.
11. McCollum AM, Austin C, Nawrocki J et al. Investigation of the first laboratory-acquired human cowpox virus infection in the United States. J Infect Dis 2012; 206: 63-8.
12. Riyesh T, Karuppusamy S, Bera BC et al. Laboratory-acquired buffalopox virus infection, India. Emerg Infect Dis 2014; 20: 324-6.
13. Laboratory-acquired vaccinia virus infection-Virginia, 2008. MMWR Morb Mortal Wkly Rep 2009; 58: 797-800.
14. Laboratory-acquired vaccinia exposures and infections-United States, 2005-2007. MMWR Morb Mortal Wkly Rep 2008; 57: 401-4.
15. Kaiser J. Six Vials of Smallpox Discovered in U.S. Lab. 2014. http://news. sciencemag.org/health/2014/07/six-vials-smallpox-discovered-u-s-lab.
16. Green A. Ebola emergency meeting establishes new control centre. Lancet 2014; 384: 118.
17. Cleton N, Koopmans M, Reimerink J et al. Come fly with me: review of clinically important arboviruses for global travelers. J Clin Virol 2012; 55:191-203.
18. Enserink M. Mission to MERS. Science 2014; 344: 1218-20.
19. Yang G, Pevear DC, Davies MH et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005; 79: 13139-49.
20. Berhanu A, King DS,Mosier S et al. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother 2009; 53: 4999-5009.
21. Duraffour S, Snoeck R, de VR et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther 2007; 12:1205-16.
22. Huggins J, Goff A, Hensley L et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009; 53: 2620-5.
23. Quenelle DC, Prichard MN, Keith KA et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007; 51: 4118-24.
24. Santos-Fernandes E, Beltrame CO, Byrd CM et al. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246w. Antiviral Res 2012; 97: 301-11.
25. Sbrana E, Jordan R, Hruby DE et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007; 76: 768-73.
26. Smith SK, Olson VA, Karem KL et al. In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother 2009; 53:1007-12.
27. Smith SK, Self J, Weiss S et al. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol 2011; 85: 9176-87.
28. Jordan R, Goff A, Frimm A et al. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother 2009; 53:1817-22.
29. Nalca A, Hatkin JM, Garza NL et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 2008; 79: 121-7.
30. Quenelle DC, Buller RM, Parker S et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007; 51: 689-95.
31. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 2012; 56: 4900-5.
32. Jordan R, Chinsangaram J, Bolken TC et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 2010; 54: 2560-6.
33. Leeds JM, Fenneteau F, Gosselin NH et al. Pharmacokinetic and pharmacodynamic modeling to determine the human dose of ST-246w to protect against smallpox. Antimicrob Agents Chemother 2012; 57: 1136-43.
34. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR et al. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob Agents Chemother 2012; 56: 3582-6.
35. Berhanu A, King DS, Mosier S et al. Impact of ST-246w on ACAM2000 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 2010; 29: 289-303.
36. Vora S, Damon I, Fulginiti V et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008; 46:1555-61.
37. Lederman ER, Davidson W, Groff HL et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012; 206: 1372-85.
38. Chen Y, Honeychurch KM, Yang G et al. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J 2009; 6: 44.
39. Smith GL. Genus Orthopoxvirus: vaccinia virus. In: Mercer AA, Schmidt A, Weber O, eds. Poxviruses. Basel: Birkhaüser, 2007; 1-45.
40. Blasco R, Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J Virol 1991; 65: 5910-20.
41. Vliegen I, Yang G, Hruby D et al. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antiviral Res 2012; 93: 160-6.
42. Grosenbach DW, Ulaeto DO, Hruby DE. Palmitylation of the vaccinia virus 37-kDa major envelope antigen. Identification of a conserved acceptor motif and biological relevance. J Biol Chem 1997; 272: 1956-64.
43. Roper RL, Moss B. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein. J Virol 1999; 73: 1108-17.
44. Schmutz C, Payne LG, Gubser J et al. A mutation in the gene encoding the vaccinia virus 37,000-Mr protein confers resistance to an inhibitor of virus envelopment and release. J Virol 1991; 65: 3435-42.
45. Isaacs SN, Wolffe EJ, Payne LG et al. Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol 1992; 66: 7217-24.
46. Engelstad M, Smith GL. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 1993; 194: 627-37.
47. Husain M, Moss B. Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles. J Virol 2001; 75: 7528-42.
48. Payne LG. Characterization of vaccinia virus glycoproteins by monoclonal antibody precipitation. Virology 1992; 187: 251-60.
49. Duraffour S, Vigne S, Vermeire K et al. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir Ther 2008; 13: 977-90.
50. Lorenzo MM, Sanchez-Puig JM, Blasco R. Mutagenesis of the palmitoylation site in vaccinia virus envelope glycoprotein B5. J Gen Virol 2012; 93:733-43.
51. Duraffour S, Andrei G, Topalis D et al. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drugsusceptibility profiles in vaccinia virus. J Virol 2012; 86: 7310-25.
52. Lorenzo MM, Galindo I, Blasco R. Construction and isolation of recombinant vaccinia virus using genetic markers. Methods Mol Biol 2004; 269: 15-30.
53. Duraffour S, Mertens B, Meyer H et al. Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. PLoS One 2013; 8: e55808.
54. Arnold K, Bordoli L, Kopp J et al. The SWISS-MODEL workspace: a webbased environment for protein structure homologymodelling. Bioinformatics 2006; 22: 195-201.
55. Bordoli L, Kiefer F, Arnold K et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat Protoc 2009; 4: 1-13.
56. Leiros I, McSweeney S, Hough E. The reaction mechanism of phospholipase D from Streptomyces sp. strain PMF. Snapshots along the reaction pathway reveal a pentacoordinate reaction intermediate and an unexpected final product. J Mol Biol 2004; 339: 805-20.
57. Benkert P, Biasini M, Schwede T. Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics 2011; 27:343-50.
58. Kelley LA, Sternberg MJ. Protein structure prediction on theWeb: a case study using the Phyre server. Nat Protoc 2009; 4: 363-71.
59. Kallberg M, Wang H, Wang S et al. Template-based protein structure modeling using the RaptorX web server. Nat Protoc 2012; 7:1511-22.
60. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83: 2915-31.
61. Herrera E, Lorenzo MM, Blasco R et al. Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain. J Virol 1998; 72:294-302.
62. Lorenzo MM, Galindo I, Griffiths G et al. Intracellular localization of vaccinia virus extracellular enveloped virus envelope proteins individually expressed using a Semliki Forest virus replicon. J Virol 2000; 74:10535-50.
63. Husain M, Moss B. Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D. J Virol 2002; 76:7777-89.
64. Carroll DS, Emerson GL, Li Y et al. Chasing Jenner's vaccine: revisiting cowpox virus classification. PLoS One 2011; 6: e23086.
65. Quenelle DC, Kern ER. Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246. Viruses 2010; 2: 2681-95.
66. Blasco R, Moss B. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol 1992; 66: 4170-9.
67. Baek SH, Kwak JY, Lee SH et al. Lipase activities of p37, the major envelope protein of vaccinia virus. J Biol Chem 1997; 272: 32042-9.